Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Operating Expenses (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Operating Expenses for 11 consecutive years, with $45.3 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 1.55% to $45.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $172.2 million through Dec 2025, up 5.47% year-over-year, with the annual reading at $172.2 million for FY2025, 5.47% up from the prior year.
  • Operating Expenses hit $45.3 million in Q4 2025 for Voyager Therapeutics, up from $44.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $45.3 million in Q4 2025 to a low of $20.1 million in Q2 2022.
  • Historically, Operating Expenses has averaged $33.3 million across 5 years, with a median of $33.1 million in 2021.
  • Biggest five-year swings in Operating Expenses: tumbled 32.94% in 2022 and later skyrocketed 56.42% in 2023.
  • Year by year, Operating Expenses stood at $22.4 million in 2021, then rose by 2.87% to $23.0 million in 2022, then surged by 56.42% to $36.0 million in 2023, then grew by 23.83% to $44.6 million in 2024, then grew by 1.55% to $45.3 million in 2025.
  • Business Quant data shows Operating Expenses for VYGR at $45.3 million in Q4 2025, $44.0 million in Q3 2025, and $41.8 million in Q2 2025.